Date published: 2026-3-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr185 Inhibitors

Olr185 inhibitors represent a distinct class of chemical compounds that specifically target and modulate the activity of the Olr185 receptor, a member of the olfactory receptor (OR) family. Olfactory receptors, primarily known for their role in the detection of odorants, are G-protein-coupled receptors (GPCRs) expressed in the sensory neurons of the olfactory epithelium. However, research has expanded their presence beyond the olfactory system, suggesting a broader physiological significance. The Olr185 receptor, like other olfactory receptors, is characterized by a seven-transmembrane domain structure, which allows it to interact with specific ligands. Inhibitors of Olr185 function by binding to the receptor and preventing the activation or downstream signaling cascades typically triggered by ligand binding. This inhibition can modulate the receptor's conformational state, interfere with the coupling to G-proteins, or block the receptor's ability to initiate signal transduction pathways. Such detailed mechanistic studies are crucial for understanding the intricate dynamics of Olr185 receptor function.

The development of Olr185 inhibitors has provided a unique tool for studying the role of this receptor in various biological processes. By selectively inhibiting Olr185, researchers can dissect the specific pathways and physiological responses mediated by this receptor, thereby shedding light on its broader biological significance. The design and synthesis of these inhibitors often involve intricate chemical modifications aimed at increasing specificity and potency. These modifications may include alterations to functional groups, stereochemistry, or molecular scaffolds to enhance the inhibitor's binding affinity for the Olr185 receptor. Additionally, advanced techniques in structural biology and computational modeling are frequently employed to predict the interaction between Olr185 and its inhibitors, guiding the rational design of more effective compounds. As a result, Olr185 inhibitors serve as a critical resource in the exploration of olfactory receptor function and the complex signaling networks in which they participate.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor; potentially alters pathways that could indirectly impact Olr185.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

mTOR inhibitor; may modulate signaling pathways indirectly affecting Olr185 activity.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits BCR-ABL, c-KIT; could influence pathways that intersect with Olr185's signaling.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multi-kinase inhibitor; may indirectly impact signaling pathways related to Olr185.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

EGFR inhibitor; might modify pathways indirectly related to Olr185.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Inhibits EGFR, HER2; could indirectly alter Olr185-related signaling pathways.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

SRC-family, BCR-ABL inhibitor; potentially affects pathways that intersect with Olr185.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL inhibitor; may indirectly influence pathways related to Olr185's activity.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-targeted receptor tyrosine kinase inhibitor; could impact signaling pathways related to Olr185.

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$197.00
$520.00
$1093.00
4
(1)

Inhibits multiple receptor tyrosine kinases; potentially modifies pathways impacting Olr185.